Table 1.
Clinicopathologic Characteristics of 212 Breast Cancer with Skeletal Metastases Patients
| Variables | Number | % |
|---|---|---|
| Age (years) | ||
| <55 | 96 | 45.3 |
| ≥55 | 116 | 54.7 |
| Pathology | ||
| Invasive ductal carcinoma | 195 | 92.0 |
| Invasive lobular carcinoma | 13 | 6.1 |
| Other | 4 | 1.89 |
| Histological Grade | ||
| I–II | 76 | 35.8 |
| III–IV | 136 | 64.2 |
| T stage | ||
| T1 | 18 | 8.5 |
| T2 | 92 | 43.4 |
| T3 | 42 | 19.8 |
| T4 | 60 | 28.3 |
| N stage | ||
| N0 | 7 | 3.3 |
| N1 | 71 | 33.50 |
| N2 | 97 | 45.7 |
| N3 | 37 | 17.5 |
| HER2 status | ||
| (-) | 87 | 41.0 |
| (+) | 125 | 59.0 |
| ER status | ||
| (-) | 92 | 43.4 |
| (+) | 120 | 56.6 |
| PR status | ||
| (-) | 146 | 68.9 |
| (+) | 66 | 31.1 |
| Ki-67 | ||
| <14% | 71 | 33.5 |
| ≥14% | 141 | 66.5 |
| The number of involved sites of visceral metastases | ||
| 0 | 106 | 50.0 |
| 1 | 20 | 9.43 |
| >1 | 86 | 40.6 |
| The number of involved sites of bone metastases | ||
| 1 | 101 | 47.6 |
| 2–3 | 90 | 42.5 |
| >3 | 21 | 9.9 |
| Site of affected bone | ||
| Femur | 15 | 7.1 |
| Rib | 51 | 24.1 |
| Lumbar spine | 39 | 18.4 |
| Thoracic spine | 78 | 36.8 |
| Humerus | 16 | 7.5 |
| Other | 13 | 6.1 |
| Type of breast cancer surgery | ||
| Breast-conserving surgery | 86 | 40.6 |
| Radical mastectomy | 126 | 59.4 |
| Number of chemotherapeutic line | ||
| First-line | 100 | 47.2 |
| Second-line | 95 | 44.8 |
| Third-line or more | 17 | 8.0 |
| Primary site radiotherapy | ||
| No | 71 | 33.5 |
| Yes | 141 | 66.5 |
| Endocrine therapy | ||
| No | 172 | 81.1 |
| Yes | 40 | 18.9 |
| Targeted therapy | ||
| No | 97 | 45.8 |
| Yes | 115 | 54.2 |
| Bisphosphonate treatment | ||
| No | 53 | 25.0 |
| Yes | 159 | 75.0 |
| Surgery to the affected bone | ||
| No | 165 | 77.8 |
| Yes | 47 | 22.2 |
| Radiotherapy to the affected bone | ||
| No | 139 | 65.6 |
| Yes | 73 | 34.4 |
| NLR | ||
| <2.48 | 90 | 42.5 |
| ≥2.48 | 122 | 57.5 |
| LMR | ||
| <3.43 | 108 | 50.9 |
| ≥3.43 | 104 | 49.1 |
| CAR | ||
| <0.34 | 168 | 79.2 |
| ≥0.34 | 44 | 20.8 |
Abbreviations: HER2, human epidermal growth factor receptor 2; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CAR, C-reactive protein/albumin ratio.